Exclusive / Gilead VP Bettina Bauer on Global HIV Research & Access Trends
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Gilead Sciences, Inc., commonly known as Gilead Sciences or Gilead (also styled GILEAD), is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Headquartered and founded in Foster City, California, Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5”…
16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses…
Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin…
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
Frederico Silva outlines the highlights of his two years heading up Gilead Sciences’ relatively young Middle-East affiliate, how Gilead has pivoted to serve evolving healthcare needs during the COVID-19 pandemic,…
Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the…
Pavel Brezina, who led the establishment of Gilead’s affiliate in the Czech Republic and Slovakia seven years ago, shares the amazing journey of bringing the company’s life-saving treatments for HIV…
Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic…
Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high…
Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5”…
With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge…
16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
A roundup of recent pharma and healthcare news from Vietnam including Gilead’s viral hepatitis initiative, the country’s explosion of dengue fever cases and the investigation into Boston Scientific’s Vietnam operations.…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin…
See our Cookie Privacy Policy Here
